Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

telaprevir

- PMLiVE

Symkevi approval in Europe helps Vertex expand CF treatment

The new combination has shown greater efficacy than Orkambi and with fewer side effects

- PMLiVE

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

Trial could begin by year end

- PMLiVE

Health secretary’s ‘rip off’ remarks anger UK pharma

Row with Vertex has tainted government-industry relations

- PMLiVE

Daily Brief: Another next-gen diabetes research deal for Novo, Vertex and Australia break deadlock

News from pharma, biotech and healthcare

- PMLiVE

Vertex appoints new commercial lead amid NHS, Orkambi price war

Ludovic Fenaux will succeed Simon Bedson

- PMLiVE

Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’

CEO writes open letter to prime minister

- PMLiVE

Vertex calls NHS England ‘outrageous’ as Orkambi talks stall again

Public row about confidential pricing talks drags on

- PMLiVE

NHS England’s Simon Stevens – no Trump drug price rhetoric here

Health service supremo will play major role in UK pricing talks

- PMLiVE

The Patient Safety Challenge

Understanding the causes of medication  errors and how to reduce them

- PMLiVE

Vertex’s Orkambi receives EU green light for licence extension

Becomes first medicine to treat the underlying cause of CF in children

- PMLiVE

Gilead wins European approval for triple hep C combination Vosevi

The treatment brings together sofosbuvir, velpatasvir and voxilaprevir

- PMLiVE

Merck & Co pulls out of hepatitis C R&D as market shrinks

Discontinues its new-generation treatments but Zepatier is still making headway

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links